Biomarker testing in MCI patients—deciding who to test

BACKGROUND: We aimed to derive an algorithm to define the optimal proportion of patients with mild cognitive impairment (MCI) in whom cerebrospinal fluid (CSF) testing is of added prognostic value. METHODS: MCI patients were selected from the Amsterdam Dementia Cohort (n = 402). Three-year progressi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Alzheimers Res Ther
Autori principali: van Maurik, Ingrid S., Rhodius-Meester, Hanneke F. M., Teunissen, Charlotte E., Scheltens, Philip, Barkhof, Frederik, Palmqvist, Sebastian, Hansson, Oskar, van der Flier, Wiesje M., Berkhof, Johannes
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2021
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7792312/
https://ncbi.nlm.nih.gov/pubmed/33413634
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-020-00763-7
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi